Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI

REFERENCES

1. 1.↵
   2. Buckner JC,
   3. Shaw EG,
   4. Pugh SL, et al

   . Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016;374:1344–55 doi:10.1056/NEJMoa1500925 pmid:27050206

   CrossRefPubMed
2. 2.↵
   2. Cairncross JG,
   3. Wang M,
   4. Jenkins RB, et al

   . Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014;32:783–90 doi:10.1200/JCO.2013.49.3726 pmid:24516018

   Abstract/FREE Full Text
3. 3.↵
   2. van den Bent MJ,
   3. Brandes AA,
   4. Taphoorn MJ, et al

   . Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344–50 doi:10.1200/JCO.2012.43.2229 pmid:23071237

   Abstract/FREE Full Text
4. 4.↵
   2. Smith JS,
   3. Perry A,
   4. Borell TJ, et al

   . Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636–45 pmid:10653879

   Abstract/FREE Full Text
5. 5.↵
   2. Lassman AB

   . Success at last: a molecular factor that informs treatment. Curr Oncol Rep 2013;15:47–55 doi:10.1007/s11912-012-0281-5 pmid:23247800

   CrossRefPubMed
6. 6.↵
   2. Louis DN,
   3. Perry A,
   4. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
7. 7.↵
   2. Eckel-Passow JE,
   3. Lachance DH,
   4. Molinaro AM, et al

   . Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499–508 doi:10.1056/NEJMoa1407279 pmid:26061753

   CrossRefPubMed
8. 8.↵
   2. Osborne AG

   . Osborne's Brain: Imaging, Pathology, and Anatomy. Salt Lake City: Amirsys; 2013:495
9. 9.↵
   2. Louis DN,
   3. Ohgaki H,
   4. Wiestler OD, et al

   . World Health Organization Histological Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer; 2007
10. 10.↵
    2. Jenkins RB,
    3. Xiao Y,
    4. Sicotte H, et al

    . A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 2012;44:1122–25 doi:10.1038/ng.2388 pmid:22922872

    CrossRefPubMed
11. 11.↵
    2. Zlatescu MC,
    3. TehraniYazdi A,
    4. Sasaki H, et al

    . Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713–15 pmid:11559541

    Abstract/FREE Full Text
12. 12.↵
    2. Laigle-Donadey F,
    3. Martin-Duverneuil N,
    4. Lejeune J, et al

    . Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 2004;63:2360–62 doi:10.1212/01.WNL.0000148642.26985.68 pmid:15623700

    CrossRefPubMed
13. 13.↵
    2. Megyesi JF,
    3. Kachur E,
    4. Lee DH, et al

    . Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303–06 doi:10.1158/1078-0432.CCR-04-0209 pmid:15240515

    Abstract/FREE Full Text
14. 14.↵
    2. Walker C,
    3. du Plessis DG,
    4. Fildes D, et al

    . Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 2004;10:7182–91 doi:10.1158/1078-0432.CCR-04-0681 pmid:15534091

    Abstract/FREE Full Text
15. 15.↵
    2. Jenkinson MD,
    3. du Plessis DG,
    4. Smith TS, et al

    . Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884–91 doi:10.1093/brain/awl108 pmid:16670176

    Abstract/FREE Full Text
16. 16.↵
    2. Jenkinson MD,
    3. Smith TS,
    4. Brodbelt AR, et al

    . Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging 2007;26:1405–12 doi:10.1002/jmri.21062 pmid:17968881

    CrossRefPubMed
17. 17.↵
    2. Brown R,
    3. Zlatescu M,
    4. Sijben A, et al

    . The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 2008;14:2357–62 doi:10.1158/1078-0432.CCR-07-1964 pmid:18413825

    Abstract/FREE Full Text
18. 18.↵
    2. Kim JW,
    3. Park CK,
    4. Park SH, et al

    . Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 2011;82:224–27 doi:10.1136/jnnp.2009.178806 pmid:20587495

    Abstract/FREE Full Text
19. 19.↵
    2. Mueller W,
    3. Hartmann C,
    4. Hoffmann A, et al

    . Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313–19 doi:10.1016/S0002-9440(10)64183-1 pmid:12107116

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Andronesi OC,
    3. Kim GS,
    4. Gerstner E, et al

    . Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012;4:116ra4 doi:10.1126/scitranslmed.3002693 pmid:22238332

    Abstract/FREE Full Text
21. 21.↵
    2. Andronesi OC,
    3. Rapalino O,
    4. Gerstner E, et al

    . Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 2013;123:3659–63 doi:10.1172/JCI67229 pmid:23999439

    CrossRefPubMedWeb of Science
22. 22.↵
    2. de la Fuente MI,
    3. Young RJ,
    4. Rubel J, et al

    . Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro Oncol 2016;18:283–90 doi:10.1093/neuonc/nov307 pmid:26691210

    Abstract/FREE Full Text
23. 23.↵
    2. Kickingereder P,
    3. Sahm F,
    4. Radbruch A, et al

    . IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 2015;5:16238 doi:10.1038/srep16238 pmid:26538165

    CrossRefPubMed
24. 24.↵
    2. Qi S,
    3. Yu L,
    4. Li H, et al

    . Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 2014;7:1895–902 pmid:24932255

    CrossRefPubMed
25. 25.↵
    2. Xiong J,
    3. Tan W,
    4. Wen J, et al

    . Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. Eur Radiol 2016;26:1705–15 doi:10.1007/s00330-015-4025-4 pmid:26396108

    CrossRefPubMed
26. 26.↵
    2. Jansen NL,
    3. Schwartz C,
    4. Graute V, et al

    . Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol 2012;14:1473–80 doi:10.1093/neuonc/nos259 pmid:23090986

    Abstract/FREE Full Text
27. 27.↵
    2. Chawla S,
    3. Krejza J,
    4. Vossough A, et al

    . Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol 2013;34:1542–49 doi:10.3174/ajnr.A3384 pmid:23370479

    Abstract/FREE Full Text
28. 28.↵
    2. Fellah S,
    3. Caudal D,
    4. De Paula AM, et al

    . Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol 2013;34:1326–33 doi:10.3174/ajnr.A3352 pmid:23221948

    Abstract/FREE Full Text
29. 29.↵
    2. Saito T,
    3. Muragaki Y,
    4. Maruyama T, et al

    . Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas. Brain Tumor Pathol 2016;33:175–82 doi:10.1007/s10014-016-0249-5 pmid:26849373

    CrossRefPubMed
30. 30.↵
    2. Khayal IS,
    3. Vandenberg SR,
    4. Smith KJ, et al

    . MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro Oncol 2011;13:1192–201 doi:10.1093/neuonc/nor122 pmid:21865401

    Abstract/FREE Full Text